Water soluble DREADD ligand clozapine N-oxide launched by Hello Bio
Bristol, UK (PRWEB UK) 13 September 2016 -- GPCRs can be modified so that they only respond to a specific biologically inert chemical (a designer drug). These modified GPCRs are called Designer Receptors Exclusively Activated by Designer Drugs or “DREADDs”. Cells expressing the DREADD respond robustly to low concentrations of the designer molecule, whereas cells that do not express the DREADD are unresponsive to the designer drug. DREADDs are functionally similar to their wild type receptors, therefore ligands such as Clozapine N-oxide (CNO), that activate DREADDs are exciting tools for the study of GPCR signaling.
CNO potently activates various muscarinic DREADD receptors. These receptors have no affinity for the endogenous ligand acetylcholine (ACh), but are responsive to CNO. CNO has no significant affinity for other CNS targets.
Clozapine N-oxide joins a range of affordable and high quality tools for GPCR research, including the novel GRK2/3 inhibitor Cmpd101, that can be used to study GPCR desensitization. Hello Bio also offers standard tools such as D-AP5.
CONTACT
For more information, please contact
Steve Roome:
hello(at)hellobio(dot)com
(0)117 3180 505
FURTHER INFORMATION
Hello Bio was founded by a team of experienced scientists and chemists who genuinely want to support life science research. Our aim is to offer a range of high quality life science tools at prices so low that as many researchers as possible will be able to afford them.
We offer a range of agonists, antagonists, inhibitors, activators, antibodies and fluorescent tools at up to half the price of other suppliers. The range includes:
Receptor ligands
Ion channel modulators
Enzyme inhibitors and activators
Epigenetic tools
Stem cell modulators, signaling tools and more...
We also offer a cost effective custom synthesis service for customers requiring specialist tools, or bulk quantities.
Steve Roome, Hello Bio, http://www.hellobio.com, +44 1173180505, [email protected]
Share this article